Back to Search
Start Over
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
- Source :
- Schoretsanitis, Georgios; Dubath, Céline; Grosu, Claire; Piras, Marianna; Laaboub, Nermine; Ranjbar, Setareh; Ansermot, Nicolas; Crettol, Séverine; Vandenberghe, Frederik; Gamma, Franziska; von Gunten, Armin; Plessen, Kerstin Jessica; Seifritz, Erich; Conus, Philippe; Eap, Chin B (2022). Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort. Basic & Clinical Pharmacology & Toxicology, 130(4):531-541.
- Publication Year :
- 2022
-
Abstract
- Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose-dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed-effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed-effects logistic regression models. In 392 olanzapine-treated patients (median age 38.0 years, interquartile range [IQR] = 26.0-53.3, median dose 10.0 mg/day, IQR = 5.0-10.0 for a median follow-up duration of 40.0 days, IQR = 20.7-112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co-prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain (p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure (p < 0.05), whereas higher doses were associated with glucose increases (p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57-2.97). EWG might be prominent in high-dose olanzapine-treated patients with treatment duration and co-prescription of other medications being weight gain moderators. The lack of major dose-dependent patterns for weight gain emphasizes that olanzapine-treated patients are at weight gain risk regardless of the dose.
Details
- Database :
- OAIster
- Journal :
- Schoretsanitis, Georgios; Dubath, Céline; Grosu, Claire; Piras, Marianna; Laaboub, Nermine; Ranjbar, Setareh; Ansermot, Nicolas; Crettol, Séverine; Vandenberghe, Frederik; Gamma, Franziska; von Gunten, Armin; Plessen, Kerstin Jessica; Seifritz, Erich; Conus, Philippe; Eap, Chin B (2022). Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort. Basic & Clinical Pharmacology & Toxicology, 130(4):531-541.
- Notes :
- application/pdf, info:doi/10.5167/uzh-229455, English, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1443050299
- Document Type :
- Electronic Resource